Claims
- 1. A compound of formula (I)
- 2. A compound according to claim 1 in which R1 represents R6N(R7)—C(═O)—NH—Ar2—.
- 3. A compound according to claim 2 in which R7 is optionally substituted phenyl.
- 4. A compound according to claim 2 in which R6 is hydrogen.
- 5. A compound according to claim 2 in which R6 is hydrogen and R7 is phenyl or ortho substituted phenyl.
- 6. A compound according to claim 5 in which R7 is phenyl substituted in the ring ortho position by C1-4 alkyl.
- 7. A compound according to claim 2 in which Ar2 is optionally substituted phenylene.
- 8. A compound according to claim 7 in which Ar2 is phenylene substituted by C1-4 alkyl or C1-4alkoxy.
- 9. A compound according to claim 7 in which Ar2 is optionally substituted p-phenylene.
- 10. A compound according to claim 8 in which Ar2 is p-phenylene substituted in the 3-position by C1-4alkyl or C1-4alkoxy.
- 11. A compound according to claim 1 in which R1 represents R5Z1—Het-.
- 12. A compound according to claim 11 in which is Het is an optionally substituted 8 to 10 membered bicyclic system
- 13. A compound according to claim 12 in which is Het is an optionally substituted 9 membered bicyclic system
- 14. A compound according to claim 13 in which Het is optionally substituted benzoxazolyl or optionally substituted benzimidazolyl.
- 15. A compound according to claim 14 in which Het is benzoxazolyl or benzimidazolyl each optionally substituted in the benzene ring by one or more groups selected from lower alkyl, lower alkoxy, amino, halogen, hydroxy, lower alkylthio, lower alkylsulphinyl, lower alkylsulphonyl, nitro or trifluoromethyl.
- 16. A compound according to claim 1 in which L1 represents a —R12—R13— linkage wherein R12 represents a straight or branched C1-4alkylene chain and R13 represents —C(═O)—NH—.
- 17. A compound according to claim 16 in which R12 represents methylene.
- 18. A compound according to claim 1 in which Ar1 represents optionally substituted p-phenylene.
- 19. A compound according to claim 18 in which Ar1 represents unsubstituted p-phenylene.
- 20. A compound according to claim 1 in which one of A1, A2 and A3 represents NR2 and the others represent CH2.
- 21. A compound according to claim 20 in which R2 is —C(═O)—R8 wherein R8 is as defined in claim 1.
- 22. A compound according to claim 21 in which R8 is C1-4alkyl or phenyl.
- 23. A compound according to claim 20 in which R2 is arylC1-4alkyl.
- 24. A compound according to claim 23 in which R2 is benzyl.
- 25. A compound according to claim 1 in which Y represents carboxy.
- 26. A compound according to claim 1 of formula (Ia):
- 27. A compound according to claim 26 in which R15 is hydrogen; X1 represents CR16 (where R16 is C1-4alkyl); X2 represents CR17 (where R17 is C1-4alkoxy); X3 represents CH; R12 is a straight C1-4alkylene chain; Ar1 is p-phenylene; Y represents carboxy; and the group containing R12 is attached at the ring 4 position.
- 28. A compound according to claim 26 in which one of A1, A2 and A3 represents NR2 and the others represent CH2.
- 29. A compound according to claim 28 in which R2 is —C(═O)—R8 wherein R8 is as defined in claim 1.
- 30. A compound according to claim 29 in which R8 is C1-4alkyl or phenyl.
- 31. A compound according to claim 28 in which R2 is arylC1-4alkyl.
- 32. A compound according to claim 31 in which R2 is benzyl.
- 33. A compound according to claim 1 of formula (Id):
- 34. A compound according to claim 33 in which R5 is optionally substituted phenyl; X is 0; R12 is a straight C1-4alkylene chain; Ar1 is p-phenylene; Y represents carboxy; and the group containing R12 is attached at the benzoxazole ring 6 position.
- 35. A compound according to claim 33 in which one of A1, A2 and A3 represents NR2 and the others represent CH2.
- 36. A compound according to claim 35 in which R2 is —C(═O)—R8 wherein R8 is as defined in claim 1.
- 37. A compound according to claim 36 in which R8 is C1-4alkyl or phenyl.
- 38. A compound according to claim 35 in which R2 is arylC1-4alkyl.
- 39. A compound according to claim 38 in which R2 is benzyl.
- 40. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 or a corresponding N-oxide, or a prodrug thereof, or a pharmaceutically acceptable salt or solvate of such a compound or its N-oxide or a prodrug thereof, in association with a pharmaceutically acceptable carrier or excipient.
- 41. A method for the treatment of a human or non-human animal patient suffering from, or subject to, a condition which can be ameliorated by the administration of an inhibitor of α4β1 mediated cell adhesion comprising administering to said patient an effective amount of a compound according to claim 1 or a corresponding N-oxide or prodrug, or a pharmaceutically acceptable salt or solvate of such a compound or an N-oxide or prodrug thereof.
- 42. A method for the treatment of a patient suffering from, or subject to, asthma comprising administering to said patient an effective amount of a compound according to claim 1 or a corresponding N-oxide or prodrug, or a pharmaceutically acceptable salt or solvate of such a compound or an N-oxide or prodrug thereof.
- 43. A method for the treatment of a patient suffering from, or subject to, an inflammatory disease comprising administering to said patient an effective amount of a compound according to claim 1 or a corresponding N-oxide or prodrug, or a pharmaceutically acceptable salt or solvate of such a compound or an N-oxide or prodrug thereof.
- 44. A method for the treatment of a human or non-human animal patient suffering from, or subject to, a condition which can be ameliorated by the administration of an inhibitor of α4β1 mediated cell adhesion comprising administering to said patient an effective amount of a composition according to claim 40.
- 45. A method for the treatment of a patient suffering from, or subject to, asthma comprising administering to said patient an effective amount of a composition according to claim 40.
- 46. A method for the treatment of a patient suffering from, or subject to, an inflammatory disease comprising administering to said patient an effective amount of a composition according to claim 40.
Priority Claims (1)
Number |
Date |
Country |
Kind |
9910419.2 |
May 1999 |
GB |
|
Parent Case Info
[0001] This application is a continuation of PCT/GBOO/01730, filed May 5, 2000, which claims priority from GB Application No. 9910419.2, filed May 5, 1999, and US Provisional Application No. 60/176,191, filed Jan. 14, 2000; all these applications incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60176191 |
Jan 2000 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/GB00/01730 |
May 2000 |
US |
Child |
10002246 |
Nov 2001 |
US |